We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Placental MicroRNAs Diagnosis Pregnancy Progress and Fetal Distress

By LabMedica International staff writers
Posted on 28 Sep 2021
Analysis of placental microRNAs (miRNAs), which also circulate in the maternal blood, represents a significant improvement to currently used pregnancy screening tools, allowing assessment of placental health, and therefore fetal health, in real time.

The critical role of the placenta in successful pregnancy is clear, and there is also evidence linking developmental programming of chronic adult disease such as heart disease, diabetes, and obesity with the placental phenotype in utero. More...
However, there are currently no non-invasive tests to determine which women are likely to develop pregnancy complications in routine use, nor is there a comprehensive reference set of miRNA expression during early pregnancy that can be used for development of pregnancy health biomarkers.

MiRNAs comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia and cardiovascular conditions.

Investigators at Flinders University (Adelaide, Australia) generated miRNA profiles using 96 placentas from presumed normal pregnancies, across early gestation, in combination with matched profiles from maternal plasma. Placenta samples ranged from six to 23 weeks’ gestation, a time period that included placenta from the early, relatively low but physiological (six to10 weeks’ gestation) oxygen environment, and later, physiologically normal oxygen environment (11 to 23 weeks’ gestation).

The results identified 637 miRNAs with expression in 86 samples. Of these, 374 were differentially expressed (DE) miRNAs between placentas from six to10 weeks’ versus 11 to 23 weeks’ gestation. Proportional change in expression of placenta-specific miRNA clusters was reflected in maternal plasma. In particular, the amount of a cluster of miRNAs from Chromosome 19, which are only made by the placenta and are present in maternal blood, changed in response to the initiation of maternal blood flow into the placenta after 10 weeks of gestation.

"Our group has had a long-term interest in developing screening tests to identify pregnant women early in pregnancy who are at risk of pregnancy complications," said senior author Dr. Claire Roberts, professor of medicine and public health at Flinders University. "The earlier we can identify those at risk the earlier we can implement extra clinical monitoring and prevention strategies."

The placenta miRNA study was published in the August 19, 2021, online edition of the journal RNA Biology.

Related Links:
Flinders University


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Staining Management Software
DakoLink
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.